Novo Nordisk A/S NVO
Regular-session close
After hours · Nov 16, 7:33 PM ET
- YTD
- -18.24%
- 1 year
- -13.80%
- Market cap
- 183.39B
- Revenue (ttm)
- 333.65B
- Profit margin
- 33.92%
- EPS (ttm)
- 3.96
- Shares out
- 3.33B
- P/E ratio
- 10.51
- Forward P/E
- 12.10
- Dividend
- 1.80 (4.32%)
- Ex-dividend date
- Aug 17, 2026
- YTD return
- -18.24%
- 1-year return
- -13.80%
- Volume
- 15.99M
- Avg volume
- 12.36M
- Open
- 42.05
- Previous close
- 41.63
- Day's range
- 41.44 – 42.30
- 52-week range
- 35.12 – 64.16
- Beta
- 0.37
- Analysts
- Hold
- Price target
- 45.39 (+9.1%)
- Earnings date
- Feb 3, 2027
- 50-day average
- 40.09
5D +0.99 (+2.44%)
Key statistics
- 200-day average
- 43.18
- Enterprise value
- 271.68B
- PEG ratio
- 4.31
- Price / sales
- 0.55
- Price / book
- 5.60
- Payout ratio
- 45.36%
- Revenue growth
- 5.60%
- Free cash flow
- 32.75B
- Total cash
- 46.35B
- Total debt
- 134.48B
- Return on equity
- 58.38%
- Short % of float
- 1.21%
Fundamental scorecard
21 of 25 checks passed on NVO’s reported financials
21of 25 checks passed
- Value 5 of 5
- Growth 4 of 5
- Profitability 4 of 5
- Financial health 3 of 5
- Dividend 5 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: hold
- Target (low)
- 39.45
- Target (mean)
- 45.39
- Target (high)
- 64.11
- Strong buy0
- Buy3
- Hold10
- Sell1
- Strong sell0
Next earnings
Feb 3, 2027
Expected Feb 3, 2027. Consensus EPS estimate 4.87.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 3, 2027 | Dec 30, 2026 | 0.68 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 0.731 | 0.89 | +0.16 | +21.75% |
| Aug 5, 2026 | Jun 30, 2026 | 0.82 | 0.96 | +0.14 | +17.07% |
| May 6, 2026 | Mar 31, 2026 | 0.87 | 1.04 | +0.17 | +19.54% |
| Feb 3, 2026 | Dec 31, 2025 | 0.90 | 1.00 | +0.10 | +11.11% |
| Nov 5, 2025 | Sep 30, 2025 | 0.77 | 1.02 | +0.25 | +32.47% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | BMO Capital | main | Market Perform | Market Perform |
| Sep 11, 2026 | Morgan Stanley | down | Equal-Weight | Underweight |
| Mar 2, 2026 | Goldman Sachs | down | Buy | Neutral |
| Feb 24, 2026 | JP Morgan | down | Overweight | Neutral |
| Jan 9, 2026 | CICC | init | — | Outperform |
| Dec 8, 2025 | Argus Research | down | Buy | Hold |
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- Denmark
- Website
- novonordisk.com
News
NVO's Hemophilia A Treatment Gets EC Nod, Data Presented on CagriSema
Novo Nordisk Showcases CagriSema Trial Gains and Wegovy Food Noise Reductions Ahead of FDA Decision
Novo Nordisk Shares Rise on Positive Weight-Loss Data, Hemophilia Drug Approval Reported Sunday, Novo Presents Two REDEFINE 1 Post Hoc Analyses Of CagriSema At ObesityWeek: 25.4% Mean Weight Loss In Early Responders, 73.1% Versus 49.1% Placebo Meaningful Physical Function Improvement
Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?
Novo Nordisk Scores EU Win For Hemophilia Drug, Advances Sickle Cell Treatment Toward Approval
4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day Novo Nordisk Submits FDA New Drug Application And EMA Marketing Authorization Application For Etavopivat For Treatment Of Adolescents And Adults With Sickle Cell Disease
Vivani Medical Advances Long-Acting Semaglutide Implant Toward Phase 2 Trial in 2027
Your note
Sign in to keep a note on NVO — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Dodge & Cox Inc. | 0.60% | 20,352,460 | 846.66M | Sep 29, 2026 |
| LOOMIS SAYLES & CO L P | 0.53% | 17,851,108 | 742.61M | Sep 29, 2026 |
| Arrowstreet Capital, Limited Partnership | 0.50% | 17,093,966 | 711.11M | Sep 29, 2026 |
| Franklin Templeton, Inc. | 0.40% | 13,472,490 | 560.46M | Sep 29, 2026 |
| Morgan Stanley | 0.38% | 13,006,793 | 541.08M | Sep 29, 2026 |
| Price (T.Rowe) Associates Inc | 0.35% | 11,704,719 | 486.92M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 0.45% | 15,240,800 | 634.02M | Jun 29, 2026 |
| PUTNAM LARGE CAP VALUE FUND | 0.24% | 7,975,159 | 331.77M | Jul 30, 2026 |
| WASHINGTON MUTUAL INVESTORS FUND | 0.16% | 5,338,458 | 222.08M | Sep 29, 2026 |
| LOOMIS SAYLES FUNDS II-Loomis Sayles Growth Fund | 0.15% | 5,111,619 | 212.64M | Jun 29, 2026 |
| AMERICAN BALANCED FUND | 0.14% | 4,750,000 | 197.60M | Sep 29, 2026 |
| TR PRICE-Price (T.Rowe) International Growth Equity Trust | 0.10% | 3,454,365 | 143.70M | Jun 29, 2026 |
